Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Australian Clinical Labs Ltd ( (AU:ACL) ).
Australian Clinical Labs Limited announced the cessation of 701,165 ordinary fully paid securities due to an on-market buy-back, effective December 5, 2025. This move is part of the company’s capital management strategy, potentially impacting its share value and market perception by reducing the number of outstanding shares.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$3.00 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Australian Clinical Labs Limited operates in the healthcare industry, focusing on providing pathology services. The company is involved in diagnostic testing and related services, catering to medical professionals and patients across Australia.
Average Trading Volume: 786,592
Technical Sentiment Signal: Buy
Current Market Cap: A$548.7M
For a thorough assessment of ACL stock, go to TipRanks’ Stock Analysis page.